Poor agreement between light transmission aggregometry, Verify Now P2Y12 and vasodilatator-stimulated phosphoprotein for clopidogrel low-response assessment: A potential explanation of negative results of recent randomized trials

Platelets

Volumn 25, Issue 7, 2014, Pages 499-505

  Lemesle, Gilles ^a   Landel, Jean Baptiste ^a   Bauters, Anne ^a   Delhaye, Cédric ^a   Bonello, Laurent ^b   Sudre, Arnaud ^a   Susen, Sophie ^a   Bauters, Christophe ^a   Lablanche, Jean Marc ^a  

^a UNIV LILLE   (France)

^b HÔPITAL NORD   (France)

Author keywords

Antiplatelet therapy tailoring; Clopidogrel response; Light transmission aggregometry; Vasodilatator stimulated phosphoprotein; Verify Now P2Y12

Indexed keywords

CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ANTITHROMBOCYTIC AGENT; CELL ADHESION MOLECULE; P2RY12 PROTEIN, HUMAN; PHOSPHOPROTEIN; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ADULT; ANALYTIC METHOD; ARTICLE; FEMALE; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PLATELET REACTIVITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE AGGREGATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; DRUG EFFECTS; DRUG MONITORING; METABOLISM; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

CELL ADHESION MOLECULES; DRUG MONITORING; FEMALE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; TICLOPIDINE;

EID: 84912000644     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2013.840363     Document Type: Article

References (33)

1. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002;252:233-238
2. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-Treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005;45: 1392-1396
3. Gurbel PA, Bliden KP, Hiatt BL, OConnor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107: 2908-2913
4. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC. High post-Treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-549
5. Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F, Barragan P, Camoin-Jau L. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007;5:1630-1636
6. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005;3:85-92
7. Patti G, Nusca A, Mangiacapra F, Gatto L, DAmbrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008;52:1128-1133
8. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drugeluting stent implantation. Eur Heart J 2008;29:992-1000
9. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175
10. Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat-Bonello C, Giacomoni MP, Bonello R, Collet F, Rossi P, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5-10
11. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-1411
12. Bliden KP, Di Chiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49:657-666
13. Blindt R, Stellbrink K, de Taeye A, Muller R, Kiefer P, Yagmur E, Weber C, Kelm M, Hoffmann R. The significance of vasodilatorstimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007;98:1329-1334
14. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:1820-1826
15. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study. J Am Coll Cardiol 2005;46:1827-1832
16. Siller-Matula JM, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G, Gouya G, Ruzicka K, Podczeck-Schweighofer A, Christ G. Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study. Int J Cardiol 2012; 167:2018-2023
17. Siller-Matula JM, Jilma B. Why have studies of tailored anti-platelet therapy failed so far? Thromb Haemost 2013;110(4) [Epub ahead of print]
18. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrie D, Boueri Z, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367:2100-2109
19. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011;305:1097-1105
20. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-Treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56: 919-933
21. Bidet A, Jais C, Puymirat E, Coste P, Nurden A, Jakubowski J, Nurden P. VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation. Platelets 2010;21:94-100
22. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754-762
23. Godino C, Mendolicchio L, Figini F, Latib A, Sharp AS, Cosgrave J, Calori G, Cera M, Chieffo A, Castelli A, Maseri A, Ruggeri ZM, Colombo A. Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy? Thromb J 2009;7:4
24. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009;101:333-339
25. Jakubowski JA, Bourguet N, Boulay-Moine D, Sugidachi A, Yamaguchi S, Barragan P, Zhou C, Moulard M. Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-Associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y(12) inhibition. Thromb Haemost 2012;107:388-395
26. Jakubowski JA, Li YG, Small DS, Payne CD, Tomlin ME, Luo J, Winters KJ. A comparison of VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: An integrated analysis. J Cardiovasc Pharmacol 2010;56:29-37
27. Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008;99:215-222
28. Kuliczkowski W, Rychlik B, Chizynski K, Watala C, Golanski J. Comparison of the VASP assay and platelet aggregometry in the evaluation of platelet P2Y12 receptor blockade. Pol Arch Med Wewn 2011;121:115-121
29. van Werkum JW, van der Stelt CA, Seesing TH, Hackeng CM, ten Berg JM. A head-To-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost 2006;4:2516-2518
30. von Beckerath N, Sibbing D, Jawansky S, Braun S, Morath T, Vogt W, Schomig A, Kastrati A. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry. Blood Coagul Fibrinolysis 2010;21:46-52
31. Gurbel PA, Antonino MJ, Bliden KP, Dichiara J, Suarez TA, Singla A, Tantry US. Platelet reactivity to adenosine diphosphate and long-Term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target. Platelets 2008;19:595-604
32. Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999;82:1145-1152
33. Armero S, Camoin Jau L, Omar Ait Mokhtar O, Mancini J, Burignat-Bonello C, Tahirou I, Arques S, Dignat-George F, Paganelli F, Bonello L. Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy. Platelets 2010;21:503-507